Estimating the budget impact of orphan drugs in Sweden and France 2013–2020

Abstract

BackgroundThe growth in expenditure on orphan medicinal products (OMP) across Europe has been identified as a concern. Estimates of future expenditure in Europe have suggested that OMPs could account for a significant proportion of total pharmaceutical expenditure in some countries, but few of these forecasts have been well validated. This analysis aims to establish a robust forecast of the future budget impact of OMPs on the healthcare systems in Sweden and France.MethodsA dynamic forecasting model was created to estimate the budget impact of OMPs in Sweden and France between 2013 and 2020. The model used historical data on OMP designation and approval rates to predict the number of new OMPs coming to the market. Average OMP sales were estimated for each year post-launch by regression analysis of historical sales data. Total forecast sales were compared with expected sales of all pharmaceuticals in each country to quantify the relative budget impact.ResultsThe model predicts that by 2020, 152 OMPs will have marketing authorization in Europe. The base case OMP budget impacts are forecast to grow from 2.7% in Sweden and 3.2% in France of total drug expenditure in 2013 to 4.1% in Sweden and 4.9% in France by 2020. The principal driver of expenditure growth is the number of new OMPs obtaining OMP designation. This is tempered by the slowing success rate for new approvals and the loss of intellectual property protection on existing orphan medicines. Given the forward-looking nature of the analysis, uncertainty exists around model parameters and sensitivity analysis found peak year budget impact varying between 2% and 11%.ConclusionThe budget impact of OMPs in Sweden and France is likely to remain sustainable over time and a relatively small proportion of total pharmaceutical expenditure. This forecast could be affected by changes in the success rate for OMP approvals, average cost of OMPs, and the type of companies developing OMPs.

A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome

“…First, CS is a component of a rare disease, and the number of total prevalent and incident patients eligible for TE was estimated at approximately 80 patients each year over the 5 years; according to market share assumptions, only 44 patients would initiate treatment with TE by year 5. This aligns with findings from a 2014 study assessing the budget impact of orphan medicinal products in Sweden and France, in which the low overall number of annual sales made the costs associated with these treatments sustainable [53]. Further to this, the TE budget impact model assumed that patients who responded to TE would gradually discontinue treatment either as the disease progressed, TE -without TE scenario Total costs, € 2,793,111 2,742,376 2,659,435 2,574,530 2,494,143 13,263,595 SSA + TE drug costs 1,565,879 1,534,877 1,486,779 1,438,271 1,392,723 7,418,528 TE 250 mg ------SSA Second, the improved diarrhoea symptom control resulting from treatment with TE translated into overall healthcare system cost savings that offset the pharmacy cost of TE, an outcome previously reported for other treatments in rare chronic diseases [54,55].…”

At the Cross Section of Thrombotic Microangiopathy and Atypical Hemolytic Uremic Syndrome: A Narrative Review of Differential Diagnostics and a Problematization of Nomenclature

“…However, eculizumab, one of the most expensive ultra‐orphan drugs available on the market today, has been subject to health economic discussions questioning approval of government coverage in several countries due to its pricing. Eculizumab plays a key role in complement inhibition and dominates treatment effectiveness in complement‐mediated aHUS.…”

Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems

“…Orphan drugs caused 2.7 % in Sweden and 3.2 % in France of total drug expenditure in 2013. A portion of 4.1 % in Sweden and 4.9 % in France was estimated by 2020 [12]. In particular, drug costs for payers are quite high due to the small number of patients treated and the unique position of the pharmaceutical companies offering orphan drugs.…”